Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03042611 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
A Phase 3 study, sponsored by Elevar Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT03042611 is a Phase 3 study that has completed, run by Elevar Therapeutics. The registered enrollment target is 460 participants.
The verdict
NCT03042611, a Phase 3 study, has completed, sponsored by Elevar Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC).
Interventions
- DRUG Placebo
- DRUG Rivoceranib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2017-03-14 |
| Est. Completion | 2020-09-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03042611
The ClinicalTrials.gov registry entry for NCT03042611 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elevar Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03042611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03042611 about?
NCT03042611 is a clinical study titled "A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer". The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC).
What is the current status of trial NCT03042611?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2017-03-14. Estimated completion is 2020-09-23.
What interventions are being tested in trial NCT03042611?
The interventions under investigation include: Placebo (DRUG), Rivoceranib (DRUG).
Who is sponsoring clinical trial NCT03042611?
This trial is sponsored by Elevar Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.